{
    "nct_id": "NCT03229083",
    "official_title": "Monitoring of Treatment Related Toxicities from Oral Targeted Agents and Immunotherapy Among Patients with Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study",
    "inclusion_criteria": "* Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease\n* Greater than 18 years of age\n* A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy\n* Able to provide written informed consent\n* Proficient in the English language and self-reports as literate\n* Must have an active email address or access to a smart device on which text messages can be received\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Women cannot be breast-feeding\n* Does not have regular access to the internet\n* Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist\n* Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change",
    "miscellaneous_criteria": ""
}